Wanbang Pharmaceutical: Summary of 2026 Semi-annual Report
Summary of the 2026 Semi-Annual Report of Anhui Wanbang Pharmaceutical Technology Co., Ltd.
Securities code: 301520 Securities abbreviation: Wanbang Pharmaceutical Announcement number: 2026-030
Anhui Wanbang Pharmaceutical Technology Co., Ltd. 2026 Semi-Annual Report Summary
1. Important tips
This summary of the semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should read the full text of the semi-annual report carefully in the media designated by the China Securities Regulatory Commission.
All directors have attended the board meeting where this report was considered.
Non-standard audit opinion tips
□Applicable Not applicable
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital reviewed by the board of directors
□Applicable Not applicable
The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.
Preferred stock profit distribution plan for the reporting period approved by the board of directors
□Applicable Not applicable
2. Basic situation of the company
- Company profile
Stock abbreviation Wanbang Pharmaceutical stock code 301520
Stock Exchange Shenzhen Stock Exchange
Contact person and contact information Secretary of the Board of Directors Name of securities affairs representative Hou Haikun
Phone 0551-68858187
Office address No. 299, Huolongdi Road, High-tech Zone, Hefei City, Anhui Province
Email [email protected]
- Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
This reporting period is better than the same period last year. This reporting period is better than the same period last year.
Increase or decrease in operating income (yuan) 87,757,664.33 146,838,210.56 -40.24% Net profit attributable to shareholders of listed companies (yuan) 137,992.87 26,811,405.38 -99.49% Net profit attributable to shareholders of listed companies excluding non-recurring gains and losses
-13,430,876.92 12,327,047.70 -208.95% profit (yuan)
Net cash flow generated from operating activities (yuan) 805,767.18 12,538,969.15 -93.57% Basic earnings per share (yuan/share) 0.0015 0.40 -99.63%
Summary of the 2026 Semi-Annual Report of Anhui Wanbang Pharmaceutical Technology Co., Ltd.
Diluted earnings per share (yuan/share) 0.0015 0.40 -99.63%
Weighted average return on equity 0.01% 1.79% -1.78%
The end of the reporting period is higher than the end of the reporting period of the previous year.
Final increase or decrease
Total assets (yuan) 1,818,725,450.62 1,602,526,442.22 13.49%
Net assets attributable to shareholders of listed companies (yuan) 1,496,560,326.03 1,515,396,152.63 -1.24%
- Number of shareholders and shareholding status of the company
Unit: Share
Voting at the end of the reporting period Special table held
Shares with preferential voting rights whose common equity is restored at the end of the reporting period
10,730 0 0 Total number of shareholders Total number of shareholders Total number of shareholders
(if any) (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Holding conditions for sale restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held
Number of shares Share status Number Tao Chunlei Domestic natural person 39.71% 36,998,920 36,998,920 Not applicable 0 Xu Xinluo Domestic natural person 14.61% 13,616,680 13,616,680 Not applicable 0 Hefei Bairibang Equity
Domestic non-state-owned
Investment partnership 7.00% 6,525,400 6,525,400 Not applicable 0
legal person
(limited partnership)
Jiangsu Tianhui Sumin Investment Co., Ltd.
Health Industry Investment Management
Management Co., Ltd.-Jiang
Others 2.35% 2,187,500 2,187,500 Not applicable 0Su Binquan Tianhui Sumin
Invest in health industry funds
(limited partnership)
Shen Ying Domestic natural person 2.10% 1,957,620 0 Not applicable 0 Hefei Hangbang Enterprise Management
Domestic non-state-owned
Management partnership (1.02% 950,530 950,530 Not applicable 0
legal person
limited partnership)
Shanghai Tianyidao Investment
Management Co., Ltd. -
Tianyi Dao Shenghong Wenjian Others 0.88% 818,180 0 Not applicable 0 No. 7 Private Securities Investment
capital fund
Sima Wenlong Domestic natural person 0.72% 668,940 0 Not applicable 0 Liumiaoxing (Beijing)
Private equity fund management has
Co., Ltd.-Liu Miao Xing Others 0.53% 492,300 0 Not applicable 0 Haoxin Zhuan No. 2 Private
Raising securities investment funds
Six Wonderful Stars (Beijing)
Private equity fund management has
Co., Ltd.-Liu Miao Xing Others 0.52% 488,500 0 Not applicable 0 Jiuzi No. 1 Private Placement Certificate
securities investment funds
Tao Chunlei and Xu Xinluo, who are related or acting in concert among the above shareholders, have a mother-son relationship. Hefei Bairibang Equity Investment Partnership (Limited Partnership) and Hefei Hang Enterprise Management Partnership (Limited Partnership) are enterprises controlled by Tao Chunlei, the controlling shareholder and actual controller.
Shanghai Tianyidao Investment Management Co., Ltd. - Tianyidao Shenghong Wenjian No. 7 Private Securities Investment Fund participates in margin financing and securities lending through the top 10 ordinary shareholders of ordinary securities
The securities account holds 0 shares, and the information on the shareholders holding the business through customer credit transactions of Zhongtai Securities Co., Ltd. (if any) is guaranteed by the securities account.
818,180 shares, a total of 818,180 shares held.
Summary of the 2026 Semi-Annual Report of Anhui Wanbang Pharmaceutical Technology Co., Ltd.
Liu Miao Xing (Beijing) Private Equity Fund Management Co., Ltd. - Liu Miao Xing Haoxin Subjective No. 2 Private Securities Investment Fund holds 0 shares through ordinary securities accounts and 492,300 shares through Guoxin Securities Co., Ltd.'s customer credit transaction guaranteed securities account, for a total of 492,300 shares.
Liu Miaoxing (Beijing) Private Equity Fund Management Co., Ltd. - Liu Miaoxing Jiuzi No. 1 Private Securities Investment Fund holds 0 shares through ordinary securities accounts and 488,500 shares through Guoxin Securities Co., Ltd.'s customer credit transaction guaranteed securities account, for a total of 488,500 shares.
Wang Junhua holds 0 shares through ordinary securities accounts and 470,140 shares through Guoxin Securities Co., Ltd.'s customer credit transaction guaranteed securities account, for a total of 470,140 shares.
Xu Fangzheng holds 0 shares through an ordinary securities account and 320,000 shares through the customer credit transaction guaranteed securities account of Cathay Haitong Securities Co., Ltd., for a total of 320,000 shares. Situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □Applicable Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
Whether the company has differential voting rights arrangements
□Yes No
- Changes in controlling shareholders or actual controllers
Changes in controlling shareholders during the reporting period
□Applicable Not applicable
The company's controlling shareholder did not change during the reporting period.
Changes in actual controller during the reporting period
□Applicable Not applicable
The actual controller of the company did not change during the reporting period.
- Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
The company has no preference shareholders’ shareholdings during the reporting period.
- Status of bonds existing on the date of approval of the semi-annual report
□Applicable Not applicable
3. Important matters
None